Analysis of market scale and competition of China Biomedical Industrial Park
Introduction: China Biomedical Industrial Park is constantly developing with the development of advanced innovation development zones. In the early 1990s, the country made a strategic decision to accelerate the development of advanced innovative technology industries. As of the end of 2019, there were 193 biomedical industrial parks in China, accounting for 49.87%, mainly in Jiangsu, Shandong, and Guangdong. The cumulative number of biomedical industrial parks in the three places reached 40, accounting for 21% of the national total. The TOP10 distribution area of the biomedical industrial park is relatively scattered, and Shanghai Zhangjiang High-tech Industrial Development Zone ranks first.
In recent years, the scale of the output value of my country's biomedical parks has been increasing year by year, with an average annual compound growth rate of 11%. The scale of the output value in 2019 is 2.2 trillion yuan. The vast majority of domestic biopharmaceutical park enterprises have weak innovation output, and only a few parks are actively applying for Class 1 new drugs.
By the end of 2019, there were 193 biomedical industrial parks in my country, accounting for 49.87%
According to statistics, as of the end of 2019, there were 168 national-level high-tech zones and 219 national-level economic and technological development zones, with a total of 387 national-level industrial parks. Among them, 193 take the bio-pharmaceutical industry as the key development direction, accounting for 49.87%.
my country's top 100 biopharmaceutical industrial parks are mainly concentrated in Jiangsu, Shandong, and Guangdong. The cumulative number of biomedical industrial parks in the three places has reached 40, accounting for 21% of the national total.
According to statistics, China's top 100 biopharmaceutical industrial parks are mainly concentrated in Jiangsu, Shandong, and Guangdong. The cumulative number of biomedical industrial parks in the three places has reached 40, accounting for 21% of the national total; the number of biomedical industrial parks in Hubei and Zhejiang is There are 6 bio-pharmaceutical industrial parks in Hunan, Jilin and Tianjin areas.
2020 my country's biomedical industrial park TOP10 distribution area is relatively scattered, Shanghai Zhangjiang High-tech Industrial Development Zone ranks first
According to CCID data, the TOP10 distribution areas of my country's biomedical industrial park in 2020 are relatively scattered. Shanghai Zhangjiang Hi-Tech Industrial Development Zone ranks first, Suzhou Industrial Park and Zhongguancun Science Park rank second and third respectively.
The scale of the output value of my country's biomedical parks has been increasing year by year, with an average annual compound growth rate of 11%. The scale of the output value in 2019 is 2.2 trillion yuan
From 2017 to 2019, the scale of the output value of my country's biopharmaceutical parks has been increasing year by year, with an average annual compound growth rate of 11%. In 2019, the scale of my country's biomedical park output value was 2.2 trillion yuan, an increase of 12.9% year-on-year. According to CCID data, the output value of my country's biomedical parks will reach 2.5 trillion yuan by 2020.
The vast majority of domestic biopharmaceutical park companies have weak innovation output, and only a few parks are actively applying for Class 1 new drugs
The vast majority of domestic biopharmaceutical park enterprises have weak innovation output, and only a few parks are actively applying for Class 1 new drugs. In 2019, there were only 11 parks with more than 10 class 1 new drug declarations, and there was a wide gap in the number of class 1 new drug declarations between the parks.
The biopharmaceutical industrial parks with more outstanding new drug declarations in 2019 are mainly Suzhou Industrial Park, Shanghai Zhangjiang High-tech Industrial Development Zone and Lianyungang Economic and Technological Development Zone, with more than 60 declarations.
Looking for chemical products? Let suppliers reach out to you!
2026-07-07
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China's Fixed-Asset Investment Up 3.8% YoY in H1 2023, Led by Chemical Industry
-
In the First Half of the Year, the Manufacturing Price of Chemical Raw Materials and Products Increased by 16.3% Year-on-year
-
Structure Of Supply Chain Of Pharmaceutical Products
-
In The First Four Months, The Investment in Chemical Raw Materials and Products Manufacturing Industry Increased by 16.2% Year-on-year
-
The Added Value of Chemical Raw Materials And Products Manufacturing in April Fell by 0.6% Year-on-year
-
In April, the Prices of Chemical Raw Materials and Products Increased by 14.9% Year-on-year and 1.4% Month-on-month.
-
The Latest Data! Total Retail Sales of Cosmetics Fell 6.3% in March
-
The Added Value of Chemical Raw Materials And Products Manufacturing In March Increased By 3.0% Year-on-year
-
If Crude Oil Plummets, Which Chemical Products Will Be 'Unbearable' First?
-
Overview of China's medical device import and export trade in 2021
Recommend Reading
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
China's urea market shows a strong upward trend (11.3-11.7)
-
MIBK Market in 2025 Stabilizes First, Then Declines; Enters Supply and Demand Optimization Stage in 2026
-
This Week Aniline Market Stabilizes and Rises (11.3-11.7) in China
-
Demand Side Enters at Lower Levels; ABS Rallies from Low Levels by End of December